The SPDR S&P Biotech ETF (XBI) has experienced a significant outflow of approximately $225.3 million, marking a 4.6% decrease in shares outstanding from 57,575,000 to 54,950,000 week-over-week. This change reflects investor movement within the ETF’s holdings, which include notable companies like Moderna Inc (MRNA) down 0.3%, Alnylam Pharmaceuticals Inc (ALNY) up 3%, and Exelixis Inc (EXEL) up 0.9%.
Over the past year, XBI’s price has ranged from a low of $66.66 to a high of $105.47, with the latest trade at $87.43. The ETF’s performance can also be monitored against its 200-day moving average.
